The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral fast melting tablets and reusable needle-free and disposable mini-needle injector systems.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
A large float allows Antares to hide a generous market cap of 270M behind a puny share price of 2.6. Antares' share price has nearly doubled this year, likely due to enthusiasm over potential FDA approval of Anturol for overactive bladder on 12/8/11. Antares also has some stake in Biosante's Libigel, so when Biosante goes up Antares will usually do the same.
I'm not too excited about Anturol. Approved or not, this is a transdermal reformulation of a medication that has been generic in the oral form for years. Of course, the company has a million and one reasons why Anturol is better than generic oral oxybutynin but I'm not convinced that urologists will buy in. In July the company partnered Anturol with Watson for undisclosed compensation, which usually means low compensation. In Q3 total development revenue was 1M, indicating that their compensation from Watson was less than 1M. Even if they are amortizing an upfront payment over several quarters, that doesn't amount to much. I'm guessing the deal was heavily backloaded, likely because Watson sees a high risk of this product not taking off commercially.
Libigel is more of a wild card. Antares has international marketing rights if Libigel is approved, and the share price could certainly pop in the short-term with positive phase III efficacy data for Libigel before the end of 2011. Long-term I don't think the commercial prospects for Libigel are good but I do have a green thumb on Biosante with the expectation of positive data. So my red thumb on Antares is somewhat contradictory in that respect. I see the upward momentum this week being somewhat excessive, and I'd like to escape the red thumb with a positive score before the Anturol PDUFA and Libigel data. If not, I might be in this for a while.
Antares is heavily promoted on Seeking Alpha by the usual crew of unscrupulous characters, so I look forward to hearing from the droids.